DR. MICHAEL T LOTZE, MD
Medical Practice in Pittsburgh, PA

6482405, Nov 19, 2002

Sep 14, 1999

09/395836

Hideaki Tahara - Tokyo, JP
Michael T. Lotze - Pittsburgh PA
Yasuhiko Nishioka - Tokushima, JP

University of Pittsburgh of the Commonwealth System of Higher Education - Pittsburgh PA

A61K 4800

424 9321, 424 932, 4353201, 435325, 435360, 435372, 435383, 435384, 435385, 514 44

The use of professional antigen presenting cells genetically modified to enhance expression of an immunostimulatory cytokine is disclosed for the treatment of individuals having tumors or infections. The genetically modified professional antigen presenting cells are injected directly at or near the site of the tumor or infection. Preferred professional antigen presenting cells include dendritic cells, and preferred immunostimulatory cytokines include interleukins such as IL-12.

2003022, Nov 27, 2003

Apr 4, 2003

10/148521

Michael Lotze - Pittsburgh PA, US

A01K067/00, A01H001/00, C12N015/82, C07H021/04, C12N015/85

800/008000, 800/278000, 536/023200, 435/455000, 435/468000

Highly efficient regulated promoters (RPs) and transactivators are provided. The RPs contain 2-8 transactivator binding domains positioned in an optimized manner with respect to each other. In a tetracycline-regulatable system, the RP displays 5- to 10-fold enhanced regulation efficiency by maintaining high maximal expression while offering 5- to 10-fold reduced basal leakiness. In transient studies, these novel promoters display over 900-fold gene regulation at 1:1 ratio of transactivator to reporter plasmid. Furthermore, these promoters preserve their regulator efficienty in the context of a single positive feedback regulatory vector that presents ease of delivery of the system for many uses, including for use in vivo and in gene therapy. Finally, humanized transactivators are provided, for example a tetracycline transactivator utilizing the human transactivational domain of NF- p65 protein fused to tetracycline repressor (terR) is provided that functions as efficiently as the tetracycline-regulated transactivator (tTA) and should reduce the potential immunogenicity of the original tTA.

2003006, Mar 27, 2003

Aug 6, 2002

10/213939

Hideaki Tahara - Tokyo, JP
Michael Lotze - Pittsburgh PA, US
Yasuhiko Nishioka - Tokushima, JP

University of Pittsburgh of the Commonwealth System of Higher Education - Pittsburgh PA

A61K048/00, C12N015/867

514/044000, 424/093210, 424/093200, 435/456000

The use of professional antigen presenting cells genetically modified to enhance expression of an immunostimulatory cytokine is disclosed for the treatment of individuals having tumors or infections. The genetically modified professional antigen presenting cells are injected directly at or near the site of the tumor or infection. Preferred professional antigen presenting cells include dendritic cells, and preferred immunostimulatory cytokines include interleukins such as IL-12.

2004024, Dec 9, 2004

Oct 15, 2003

10/688845

Michael Lotze - Pittsburgh PA, US
Hideaki Tahara - Tokyo, JP

University of Pittsburgh of Commonwealth System of Higher Education - Pittsburgh PA

A61K048/00, A61K038/20

424/093210, 514/044000, 424/085200

Methods and reagents for treating tumors, metastases, and infectious lesions by co-administration of antigen presenting cells and immunostimulatory cytokines or nucleic acid encoding an immunostimulatory cytokine into or near the site of the tumor or infectious lesion are described.

5989565, Nov 23, 1999

Jun 7, 1995

8/474120

Walter J. Storkus - Glenshaw PA
Michael T. Lotze - Pittsburgh PA

University of Pittsburgh - Pittsburgh PA

A61K 3400, A61K 3900, C07K 500, C12P 2102

4242771

Methods are provided for eluting peptides that are bound to major histocompatibility complex ("MHC") molecules expressed on the cell surfaces of viable cells that have at least one MHC-peptide complex on the surfaces of the cells, the method comprising incubating the cells in the presence of peptide elution buffer, preferably comprising iso-osmotic, citrate-phosphate buffer at a pH of approximately 3. 3, for between about 15 seconds and one minute. Using these methods a naturally processed melanoma peptide recognized by CD8. sup. + cytotoxic T lymphocytes has been identified.